A Study to Learn About Ritlecitinib for the Potential Treatment of Chronic Spontaneous Urticaria in Adults.
← catalyst calendarNCT07219615 · readout in 128 d
Sponsored by Pfizer (industry) · PFE — their whole pipeline →.
Phase
Phase 2
Status
Recruiting
Study type
Interventional
Design
Randomized · Quadruple · Treatment
Enrollment
200estimated
Sites
69
Countries
Bulgaria, Canada, China +7
Every value on this page is a field the sponsor filed with ClinicalTrials.gov, reproduced. Dates are their own estimates, revised as a study runs, unless the registry marks them actual. sources →
Source: ClinicalTrials.gov, retrieved 2026-08-19
Dates
each axis at the precision it was filed, with the registry's own basis| Date | Filed | Basis | What it is |
|---|---|---|---|
| Start | 2025-10-30 | actual | When the study began enrolling |
| Primary completion | 2026-12-25 | estimated | The date the last participant is measured for the primary outcome — the readout window |
| Study completion | 2027-04-23 | estimated | The whole study's end, after follow-up |
| First posted | 2025-10-22 | actual | When this record first appeared on the registry |
| Results posted | — | When the sponsor posted results to the registry | |
| Record updated | 2026-06-17 | actual | The sponsor's own last edit to this record — every projection above is as current as this date |
What it studies
Condition
- Chronic Spontaneous Urticaria
Interventions
- Drug: Ritlecitinib 50 mg — also filed as PF-06651600, Litfulo
- Drug: Ritlecitinib 100 mg — also filed as PF-06651600, Litfulo
- Drug: Placebo - 50 mg
- Drug: Placebo - 100 mg
Primary outcomes
what the primary-completion date above is the date OFChange from baseline in Urticaria Activity Score 7 (UAS7) at Week 12
measured Week 12
Incidence of Treatment Emergent Adverse Events, Serious Adverse Events, and Adverse Events leading to discontinuation
measured Week 12
Permalink · PFE's whole pipeline · Catalyst calendar · Every registered study · What changed